方盛制药公告，全资子公司方盛健盟化药仿制药研发项目瑞卢戈利片收到国家药品监督管理局核准签发 的《药物临床试验批准通知书》。瑞卢戈利片为一种促性腺激素释放激素（GnRH）受体拮抗剂，用于 治疗成人晚期前列腺癌。截至公告日，该药品项目的研发投入累计约389万元（未经审计）。瑞卢戈利 片2023年全球销售金额为3亿美元，同比增长率为58.6%。药品从研制、临床试验报批到投产的周期 长、环节多，药品研发及至上市容易受到一些不确定性因素的影响。 ...

方盛制药所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：增持回购、基金重仓、养老 产业、小盘、医疗美容等。 10月14日，方盛制药盘中上涨2.02%，截至10:04，报12.13元/股，成交6102.12万元，换手率1.16%，总 市值53.26亿元。 资金流向方面，主力资金净流入369.62万元，特大单买入750.20万元，占比12.29%，卖出794.28万元， 占比13.02%；大单买入1374.86万元，占比22.53%，卖出961.16万元，占比15.75%。 方盛制药今年以来股价涨21.18%，近5个交易日涨1.34%，近20日涨7.44%，近60日涨18.57%。 资料显示，湖南方盛制药股份有限公司位于湖南省长沙市国家高新技术产业开发区嘉运路299号，成立 日期1997年10月13日，上市日期2014年12月5日，公司主营业务涉及心脑血管中成药、骨伤科药、儿科 药、抗感染药等药品的研发、生产与销售。主营业务收入构成为：销售商品94.62%，提供服务5.38%。 截至6月30日，方盛制药股东户数3.31万，较上期增加0.37%；人均流通股13245股，较上期减少0.36%。 2025年 ...

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. has signed a contract with Liao Ning Yifan Pharmaceutical Co., Ltd. to acquire the marketing authorization for "Compound Dexamethasone Cream," which includes ownership of the drug formula, production process, technical secrets, and related patents and data [2][11]. Group 1: Transaction Overview - The company has entered into a technology transfer contract to acquire the marketing authorization for "Compound Dexamethasone Cream" [2]. - The transaction does not constitute a related party transaction or a major asset restructuring, and it is within the approval authority of the chairman, thus not requiring board or shareholder approval [2]. - The transfer fee is structured in three phases, with 30% payable within five working days of signing, another 30% upon completion of production site change, and 40% after receiving the approval notice from the drug review center [8]. Group 2: Market Situation - There are 103 companies in China that have obtained production licenses for "Compound Dexamethasone Cream" [3]. - The sales figures for the cream in physical pharmacies were 175 million yuan in the first half of 2025 and projected to reach 429 million yuan in 2024 [3]. - The global market sales for dexamethasone formulations were approximately $1.198 billion in 2022 and $1.203 billion in 2023 [3]. Group 3: Impact on the Company - The acquisition aligns with the company's strategy to become a health industry group focused on innovative traditional Chinese medicine, enhancing its product pipeline and potentially providing new profit growth points [11]. - The addition of this dermatological product category is expected to strengthen the company's market competitiveness and facilitate industry chain integration and expansion [11].

Group 1 - Changyuan Power reported a power generation of 2.742 billion kWh in September, a year-on-year decrease of 41.88% [1] - The cumulative power generation from January to September was 27.332 billion kWh, down 8.24% year-on-year [1] - Huanyu Electronics achieved a consolidated revenue of 5.96 billion yuan in September, a year-on-year increase of 0.1% [1][2] Group 2 - Zhonghuan Environmental announced a change in controlling shareholder, with 27.5% of shares being transferred for a total consideration of 598 million yuan [2] - *ST Songfa's subsidiary signed contracts for the construction of 6 VLCCs, with a total contract value of approximately 600-900 million USD [1][3] - Suzhou Xinchen Technology's subsidiary plans to acquire 55% of Kunyu Lancheng for 74.25 million yuan [3] Group 3 - Guiguan Power reported a cumulative power generation of 31.848 billion kWh for the first three quarters, a year-on-year increase of 14.89% [4] - Jincheng Pharmaceutical's subsidiary received approval for the market launch of a raw material drug [4] - Shandong Steel expects a net profit of approximately 140 million yuan for the first three quarters, an increase of about 21.96 million yuan year-on-year [4][5] Group 4 - Xiangjia Co. reported sales revenue of 96.6186 million yuan from live poultry in September, with a sales price of 12.10 yuan/kg [6] - Aonong Bio's pig sales volume in September increased by 12.2% year-on-year, with a total of 164,400 pigs sold [7] - Mingtai Aluminum's aluminum plate and foil sales reached 1.1747 million tons in the first three quarters [8] Group 5 - Guangzhou Port expects to complete a container throughput of 2.051 million TEUs in September, a year-on-year decrease of 0.8% [11] - Jiangsu Sop plans to conduct a month-long maintenance on several production units starting October 10 [12] - Baike Bio received approval for a clinical trial of a combined vaccine for infants [13] Group 6 - Yutong Bus reported a 25.55% year-on-year increase in bus sales in September, totaling 4,756 units [16] - Shanghai Rural Commercial Bank's vice chairman and president's qualifications were approved [19] - Huayu Pharmaceutical's product received market approval in four countries [20] Group 7 - Longan Automobile reported a 24.92% year-on-year increase in vehicle sales in September, totaling 266,300 units [38] - Chip Origin expects a third-quarter revenue of 1.284 billion yuan, a year-on-year increase of 78.77% [39] - Bomaike signed a contract for an offshore floating production storage and offloading vessel project, with a contract value of approximately 190-240 million USD [40]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has signed a technology transfer contract with Yifan Pharmaceutical to acquire the marketing authorization for "Compound Dexamethasone Acetate Cream," which includes ownership of the drug prescription, production process, technical secrets, related patents, and technical data [1] Group 1: Strategic Development - The company aims to become a health industry group centered on innovative traditional Chinese medicine, continuously increasing R&D investment while also acquiring products with development potential to enrich its product pipeline [1] - The acquisition of the marketing authorization is aligned with the company's development strategy, facilitating industry chain integration and expansion, thereby enhancing market competitiveness [1] Group 2: Product Expansion - Following the acquisition, the company's dermatological product category will be effectively expanded, with the potential for new profit growth through brand empowerment within the group [1]

公司确定"打造成为一家以中药创新药为核心的健康产业集团"的发展战略以来，持续加大研发投入，并 同步通过外购来储备具有发展潜力的产品，以丰富公司产品管线，从而加快发展步伐。本次受让完成 后，公司皮肤病药物品类得到有效扩充，后续通过集团的品牌赋能，有望为公司提供新的利润增长点。 本次受让药品上市许可符合公司发展战略，有利于推动产业链整合和扩张，提升公司的市场竞争力。 智通财经APP讯，方盛制药(603998.SH)发布公告，2025年9月30日，公司与亿帆药业签订了《技术转让 (技术秘密)合同》，决定受让其"复方醋酸地塞米松乳膏"药品上市许可(包括但不限于药品处方、生产工 艺、技术秘密、与标的品种相关的专利、技术资料等数据的所有权)。 ...

湖南方盛制药股份有限公司 HUNANFANGSHENGPHARMACEUTICALCO.,LTD. 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 9 月 30 日，公司与亿帆药业签订了《技术转让（技术秘密）合同》， 决定受让其"复方醋酸地塞米松乳膏"药品上市许可（包括但不限于药品处方、生产工 艺、技术秘密、与标的品种相关的专利、技术资料等数据的所有权）； 本次交易不构成关联交易，亦未构成重大资产重组；交易实施不存在重大法律 障碍，根据《公司章程》规定，该事项在董事长审批权限内，无需经董事会、股东会审 议批准； 风险提示：本次受让药品上市许可，尚需办理药品上市许可持有人变更手续， 办理完成时间具有不确定性，预计不会对公司当期经营产生重大影响；药品未来的具体 销售情况可能受到市场环境变化等因素影响，具有不确定性，敬请广大投资者谨慎决策， 注意防范投资风险 证券代码：603998 证券简称：方盛制药 公告编号：2025-083 湖南方盛制药股份有限公司 关于受让药品上市许可的公告 一、交易概述 1、标 ...

Core Viewpoint - Fangsheng Pharmaceutical (603998) announced on October 9 that it signed a technology transfer contract with Yifan Pharmaceutical on September 30, acquiring the marketing authorization for "Compound Dexamethasone Acetate Cream" [1] Group 1 - The acquired drug is indicated for localized pruritus, neurodermatitis, contact dermatitis, seborrheic dermatitis, and chronic eczema [1]

Core Viewpoint - The transaction between Fangsheng Pharmaceutical and Yifan Pharmaceutical involves the acquisition of the marketing authorization for "Compound Dexamethasone Acetate Cream," which is expected to enhance the company's product portfolio in dermatology and potentially serve as a new profit growth point [1] Group 1: Transaction Details - The contract was signed on September 30, 2025, and does not constitute a related party transaction or a major asset restructuring, falling within the chairman's approval authority [1] - The payment for the transaction will be made in three phases, indicating a structured financial approach to the acquisition [1] Group 2: Market Context - The drug is used for various skin diseases, with 103 companies in China holding production licenses for it [1] - In the first half of 2025, the sales revenue from physical pharmacies for this drug reached 175 million yuan, highlighting its market potential [1] Group 3: Strategic Implications - The acquisition aligns with the company's development strategy to expand its dermatological product offerings, which is expected to contribute positively to future revenue streams [1] - However, the timeline for completing the holder change procedures remains uncertain, and sales may be influenced by market factors, necessitating cautious decision-making by investors [1]

每经AI快讯，10月9日，方盛制药（603998）(603998.SH)公告称，方盛制药与辽宁亿帆药业签订《技术 转让（技术秘密）合同》，受让其"复方醋酸地塞米松乳膏"药品上市许可。该药品主要用于局限性搔痒 症、神经性皮炎等。交易金额在公司董事长审批权限范围内，无需经董事会、股东会审议批准。受让完 成后，公司皮肤病药物品类得到有效扩充，有望提供新的利润增长点。 ...